 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
Following CLIA Lab Buy, Life Tech Jumps into MDx Space with Purchase of Pinpoint, Lung Cancer Dx
July 25, 2012
Following CLIA Lab Buy, Life Tech Jumps into MDx Space with Purchase of Pinpoint, Lung Cancer Dx
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Life Tech to Market Dx Version of QuantStudio Platform; Developing Assays with Quidel
July 26, 2012 / PCR Insider - Life Tech Continues to Gather Evidence Backing NSCLC Dx Pervenio, As Commercialization Progresses
February 6, 2013 / Pharmacogenomics Reporter - Life Tech Genetic Analysis Revenues Decline as qPCR Royalties Wither, Though QuantStudio Sales Spike
August 2, 2012 / PCR Insider - Life Tech Sees Clinical Promise for NGS Panels, Exomes; Says Multiple Platforms to Drive Dx Strategy
August 1, 2012 / Clinical Sequencing News - Life Technologies Acquires Lung Cancer Test Developer Pinpoint Genomics
July 25, 2012 / GenomeWeb Daily News